APO Research
Talk to an analyst

APO RESEARCH · REPORT

SARS-CoV-2 IgG (RBD) ELISA

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global SARS-CoV-2 IgG (RBD) ELISA Market Outlook and Growth Opportunities 2026

30 December 2025190 pages

Choose your research edition.

Industry ResearchSARS-CoV-2 IgG (RBD) ELISA Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal SARS-CoV-2 IgG (RBD) ELISA Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal SARS-CoV-2 IgG (RBD) ELISA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SARS-CoV-2 IgG (RBD) ELISA Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal SARS-CoV-2 IgG (RBD) ELISA Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global SARS-CoV-2 IgG (RBD) ELISA market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for SARS-CoV-2 IgG (RBD) ELISA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SARS-CoV-2 IgG (RBD) ELISA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SARS-CoV-2 IgG (RBD) ELISA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the SARS-CoV-2 IgG (RBD) ELISA market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the SARS-CoV-2 IgG (RBD) ELISA market include ALPCO, BD Biosciences, BioMérieux, Bio-Rad Laboratories, Enzo Life Sciences, LG, LOEWE Biochemica, Ortho Clinical Diagnostics and R&D Systems, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global SARS-CoV-2 IgG (RBD) ELISA market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SARS-CoV-2 IgG (RBD) ELISA and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SARS-CoV-2 IgG (RBD) ELISA revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global SARS-CoV-2 IgG (RBD) ELISA market.

SARS-CoV-2 IgG (RBD) ELISA Segment by Company

ALPCO

BD Biosciences

BioMérieux

Bio-Rad Laboratories

Enzo Life Sciences

LG

LOEWE Biochemica

Ortho Clinical Diagnostics

R&D Systems

Shenzhen YHLO Biotech

ZEUS Scientific

Thermo Fisher Scientific

SARS-CoV-2 IgG (RBD) ELISA Segment by Type

ELISA Sets

ELISA Kits

SARS-CoV-2 IgG (RBD) ELISA Segment by Application

Hospital

Clinic

Disease control and prevention system

SARS-CoV-2 IgG (RBD) ELISA Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global SARS-CoV-2 IgG (RBD) ELISA status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the SARS-CoV-2 IgG (RBD) ELISA key companies, revenue, market share, and recent developments.

3. To split the SARS-CoV-2 IgG (RBD) ELISA breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions SARS-CoV-2 IgG (RBD) ELISA market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify SARS-CoV-2 IgG (RBD) ELISA significant trends, drivers, influence factors in global and regions.

6. To analyze SARS-CoV-2 IgG (RBD) ELISA competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-CoV-2 IgG (RBD) ELISA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SARS-CoV-2 IgG (RBD) ELISA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-CoV-2 IgG (RBD) ELISA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global SARS-CoV-2 IgG (RBD) ELISA industry.

Chapter 3: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of SARS-CoV-2 IgG (RBD) ELISA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of SARS-CoV-2 IgG (RBD) ELISA in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. SARS-CoV-2 IgG (RBD) ELISA Industry Trends Table 2. SARS-CoV-2 IgG (RBD) ELISA Industry Drivers Table 3. SARS-CoV-2 IgG (RBD) ELISA Industry Opportunities and Challenges Table 4. SARS-CoV-2 IgG (RBD) ELISA Industry Restraints Table 5. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Company (US$ Million) & (2021-2026) Table 6. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Company (2021-2026) Table 7. Global SARS-CoV-2 IgG (RBD) ELISA Company Ranking, (2024-2026) & (US$ Million) Table 8. Global SARS-CoV-2 IgG (RBD) ELISA Key Company Manufacturing Base & Headquarters Table 9. Global SARS-CoV-2 IgG (RBD) ELISA Company, Product Type & Application Table 10. Global SARS-CoV-2 IgG (RBD) ELISA Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global SARS-CoV-2 IgG (RBD) ELISA by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ELISA Sets Table 15. Significant Companies of ELISA Kits Table 16. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type (2021-2026) Table 20. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Disease control and prevention system Table 24. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application (2021-2026) Table 28. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application (2027-2032) Table 29. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Region (2021-2026) Table 32. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Region (2027-2032) Table 34. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Market Share by Country (2021-2026) Table 37. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Market Share by Country (2027-2032) Table 39. ALPCO Company Information Table 40. ALPCO Business Overview Table 41. ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 43. ALPCO Recent Development Table 44. BD Biosciences Company Information Table 45. BD Biosciences Business Overview Table 46. BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 48. BD Biosciences Recent Development Table 49. BioMérieux Company Information Table 50. BioMérieux Business Overview Table 51. BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 53. BioMérieux Recent Development Table 54. Bio-Rad Laboratories Company Information Table 55. Bio-Rad Laboratories Business Overview Table 56. Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 58. Bio-Rad Laboratories Recent Development Table 59. Enzo Life Sciences Company Information Table 60. Enzo Life Sciences Business Overview Table 61. Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 63. Enzo Life Sciences Recent Development Table 64. LG Company Information Table 65. LG Business Overview Table 66. LG SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 68. LG Recent Development Table 69. LOEWE Biochemica Company Information Table 70. LOEWE Biochemica Business Overview Table 71. LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 73. LOEWE Biochemica Recent Development Table 74. Ortho Clinical Diagnostics Company Information Table 75. Ortho Clinical Diagnostics Business Overview Table 76. Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 78. Ortho Clinical Diagnostics Recent Development Table 79. R&D Systems Company Information Table 80. R&D Systems Business Overview Table 81. R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 83. R&D Systems Recent Development Table 84. Shenzhen YHLO Biotech Company Information Table 85. Shenzhen YHLO Biotech Business Overview Table 86. Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 88. Shenzhen YHLO Biotech Recent Development Table 89. ZEUS Scientific Company Information Table 90. ZEUS Scientific Business Overview Table 91. ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 93. ZEUS Scientific Recent Development Table 94. Thermo Fisher Scientific Company Information Table 95. Thermo Fisher Scientific Business Overview Table 96. Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 98. Thermo Fisher Scientific Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. SARS-CoV-2 IgG (RBD) ELISA Product Image Figure 2. Global SARS-CoV-2 IgG (RBD) ELISA Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032) & (US$ Million) Figure 4. Global SARS-CoV-2 IgG (RBD) ELISA Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ELISA Sets Image Figure 8. ELISA Kits Image Figure 9. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Disease control and prevention system Image Figure 15. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application (2021-2032) Figure 18. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032) & (US$ Million) Figure 21. North America SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032) & (US$ Million) Figure 23. Europe SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032) & (US$ Million) Figure 27. South America SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • ELISA Sets
  • ELISA Kits
Applications
  • Hospital
  • Clinic
  • Disease control and prevention system
Companies covered
  • ALPCO
  • BD Biosciences
  • BioMérieux
  • Bio-Rad Laboratories
  • Enzo Life Sciences
  • LG
  • LOEWE Biochemica
  • Ortho Clinical Diagnostics
  • R&D Systems
  • Shenzhen YHLO Biotech
  • ZEUS Scientific
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 SARS-CoV-2 IgG (RBD) ELISA Market Dynamics
  1. 2.1 SARS-CoV-2 IgG (RBD) ELISA Industry Trends
  2. 2.2 SARS-CoV-2 IgG (RBD) ELISA Industry Drivers
  3. 2.3 SARS-CoV-2 IgG (RBD) ELISA Industry Opportunities and Challenges
  4. 2.4 SARS-CoV-2 IgG (RBD) ELISA Industry Restraints
3 SARS-CoV-2 IgG (RBD) ELISA Market by Company
  1. 3.1 Global SARS-CoV-2 IgG (RBD) ELISA Company Revenue Ranking in 2025
  2. 3.2 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Company (2021-2026)
  3. 3.3 Global SARS-CoV-2 IgG (RBD) ELISA Company Ranking (2024-2026)
  4. 3.4 Global SARS-CoV-2 IgG (RBD) ELISA Company Manufacturing Base and Headquarters
  5. 3.5 Global SARS-CoV-2 IgG (RBD) ELISA Company Product Type and Application
  6. 3.6 Global SARS-CoV-2 IgG (RBD) ELISA Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 SARS-CoV-2 IgG (RBD) ELISA Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 SARS-CoV-2 IgG (RBD) ELISA Market by Type
  1. 4.1 SARS-CoV-2 IgG (RBD) ELISA Type Introduction
  2. 4.1.1 ELISA Sets
  3. 4.1.2 ELISA Kits
  4. 4.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type
  5. 4.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2021-2032)
  7. 4.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type (2021-2032)
5 SARS-CoV-2 IgG (RBD) ELISA Market by Application
  1. 5.1 SARS-CoV-2 IgG (RBD) ELISA Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Disease control and prevention system
  5. 5.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application
  6. 5.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2021-2032)
  8. 5.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application (2021-2032)
6 SARS-CoV-2 IgG (RBD) ELISA Regional Value Analysis
  1. 6.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region (2021-2032)
  3. 6.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region: 2021-2026
  4. 6.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032)
  7. 6.3.2 North America SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032)
  10. 6.4.2 Europe SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032)
  16. 6.6.2 South America SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2025 VS 2032
7 SARS-CoV-2 IgG (RBD) ELISA Country-level Value Analysis
  1. 7.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2021-2032)
  3. 7.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2021-2026)
  4. 7.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ALPCO
  2. 8.1.1 ALPCO Company Information
  3. 8.1.2 ALPCO Business Overview
  4. 8.1.3 ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  6. 8.1.5 ALPCO Recent Developments
  7. 8.2 BD Biosciences
  8. 8.2.1 BD Biosciences Company Information
  9. 8.2.2 BD Biosciences Business Overview
  10. 8.2.3 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  12. 8.2.5 BD Biosciences Recent Developments
  13. 8.3 BioMérieux
  14. 8.3.1 BioMérieux Company Information
  15. 8.3.2 BioMérieux Business Overview
  16. 8.3.3 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  18. 8.3.5 BioMérieux Recent Developments
  19. 8.4 Bio-Rad Laboratories
  20. 8.4.1 Bio-Rad Laboratories Company Information
  21. 8.4.2 Bio-Rad Laboratories Business Overview
  22. 8.4.3 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  24. 8.4.5 Bio-Rad Laboratories Recent Developments
  25. 8.5 Enzo Life Sciences
  26. 8.5.1 Enzo Life Sciences Company Information
  27. 8.5.2 Enzo Life Sciences Business Overview
  28. 8.5.3 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  30. 8.5.5 Enzo Life Sciences Recent Developments
  31. 8.6 LG
  32. 8.6.1 LG Company Information
  33. 8.6.2 LG Business Overview
  34. 8.6.3 LG SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  36. 8.6.5 LG Recent Developments
  37. 8.7 LOEWE Biochemica
  38. 8.7.1 LOEWE Biochemica Company Information
  39. 8.7.2 LOEWE Biochemica Business Overview
  40. 8.7.3 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  42. 8.7.5 LOEWE Biochemica Recent Developments
  43. 8.8 Ortho Clinical Diagnostics
  44. 8.8.1 Ortho Clinical Diagnostics Company Information
  45. 8.8.2 Ortho Clinical Diagnostics Business Overview
  46. 8.8.3 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  48. 8.8.5 Ortho Clinical Diagnostics Recent Developments
  49. 8.9 R&D Systems
  50. 8.9.1 R&D Systems Company Information
  51. 8.9.2 R&D Systems Business Overview
  52. 8.9.3 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  53. 8.9.4 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  54. 8.9.5 R&D Systems Recent Developments
  55. 8.10 Shenzhen YHLO Biotech
  56. 8.10.1 Shenzhen YHLO Biotech Company Information
  57. 8.10.2 Shenzhen YHLO Biotech Business Overview
  58. 8.10.3 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  60. 8.10.5 Shenzhen YHLO Biotech Recent Developments
  61. 8.11 ZEUS Scientific
  62. 8.11.1 ZEUS Scientific Company Information
  63. 8.11.2 ZEUS Scientific Business Overview
  64. 8.11.3 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  66. 8.11.5 ZEUS Scientific Recent Developments
  67. 8.12 Thermo Fisher Scientific
  68. 8.12.1 Thermo Fisher Scientific Company Information
  69. 8.12.2 Thermo Fisher Scientific Business Overview
  70. 8.12.3 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  72. 8.12.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst